TPIV 200: Ph II started

TapImmune began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 500 µg intradermal TPIV 200 as consolidation treatment plus GM-CSF adjuvant monthly for 6 months in about 80 patient...